About Zinc finger protein 280B
Zinc finger protein 280B (ZNF280B) is a protein
from Homo sapiens identified by UniProt accession
Q86YH2, 543 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Zinc finger protein 280B |
| UniProt accession | Q86YH2 |
| Gene | ZNF280B |
| Organism | Homo sapiens |
| Length | 543 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (14)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.29
- Myopia · score 0.24
- age at onset · score 0.24
- testosterone measurement · score 0.18
- exstrophy-epispadias complex · score 0.12
- ovarian carcinoma · score 0.01
- neoplasm · score 0.01
- adrenal cortex carcinoma · score 0.00
- goblet cell carcinoma · score 0.00
- Vitiligo · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86YH2-F1 | alphafold | PREDICTED | 59.09 | — |
Amino-acid sequence (543 residues)
MEQSCEEEKE PEPQKNIQET KQVDDEDAEL IFVGVEHVNE DAELIFVGVT SNSKPVVSNI LNRVTPGSWS RRKKYDHLRK DTARKLQPKS HETVTSEAVT VLPASQLESR STDSPIIIEP LSKPDYRNSS PQVVPNNSSE LPSPLITFTD SLHHPVSTAL SVGGINESPR VSKQLSTFEV NSINPKRAKL RDGIIEGNSS ASFPSDTFHT MNTQQSTPSN NVHTSLSHVQ NGAPFPAAFP KDNIHFKPIN TNLDRANELA KTDILSLTSQ NKTFDPKKEN PIVLLSDFYY GQHKGEGQPE QKTHTTFKCL SCVKVLKNVK FMNHVKHHLE FEKQRNDSWE NHTTCQHCHR QFPTPFQLQC HIENVHTAQE PSTVCKICEL SFETDQVLLQ HMKDHHKPGE MPYVCQVCHY RSSVFADVET HFRTCHENTK NLLCPFCLKI FKTATPYMCH YRGHWGKSAH QCSKCRLQFL TFKEKMEHKT QCHQMFKKPK QLEGLPPETK VTIQVSLEPL QPGSVDVASI TVSTSDSEPS LPRSKSKISK KSH
Explore Zinc finger protein 280B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets